Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4442210 | 0.89 | LMNA (0.44) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL18710400 | 0.82 | LMNA (0.42) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL4660383 | 0.82 | LMNA (0.42) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL8613489 | 0.79 | LMNA (0.44) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL29519 | 0.78 | LMNA (0.38) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL27313158 | 0.76 | LMNA (0.45) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL22117119 | 0.74 | LMNA (0.33) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL20641588 | 0.74 | MEN1 (0.39) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL3783240 | 0.72 | ALDH1A1 (0.39) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 | |
| SCHEMBL597801 | 0.72 | ALDH1A1 (0.39) | LMNACYP3A4CYP2C9ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198292-B2 | Vinpocetine and eburnamonine derivatives for promoting bone growth, treating renal damage and cancer, and devices thereof | OSTEOGENEX, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20100003324-A1 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | OSTEOGENEX INC. (US) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003324-A1 | VINPOCETINE AND EBURN AMONINE DERIVATIVES FOR PROMOTING BONE GROWTH | BMP6, ATP6V1B1, WNT1 | LMNA 4135/4885CYP3A4 3615/4885CYP2C9 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.